Hemogenyx Pharmaceuticals PLC announces Total Voting Rights

Rhea-AI Summary

Hemogenyx Pharmaceuticals has reported that as of May 28, 2021, its total issued share capital stands at 979,749,321 ordinary shares of 1 pence each, with no shares held in treasury. This figure represents the total number of voting rights in the company. Shareholders are advised to use this number as a denominator for any calculations regarding their investment obligations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Positive

• Total issued share capital is reported at 979,749,321 ordinary shares, ensuring clarity in voting rights for shareholders.

Negative

• None.

LONDON, UK / ACCESSWIRE / May 28, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 28 May 2021 consists of 979,749,321 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 979,749,321.

The figure of 979,749,321 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View source version on accesswire.com:
https://www.accesswire.com/649566/Hemogenyx-Pharmaceuticals-PLC-announces-Total-Voting-Rights

FAQ

What is the total number of voting rights in Hemogenyx Pharmaceuticals as of May 28, 2021?

As of May 28, 2021, the total number of voting rights in Hemogenyx Pharmaceuticals is 979,749,321.

Why is the total issued share capital important for shareholders of HOPHF?

The total issued share capital is crucial as it provides the denominator for shareholders to determine if they need to notify changes in their investment under the Financial Conduct Authority's rules.

How many ordinary shares does Hemogenyx Pharmaceuticals have?

Hemogenyx Pharmaceuticals has 979,749,321 ordinary shares of 1 pence each as of May 28, 2021.